Celyad Oncology マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Matt Kane

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	7.8yrs

経営陣の近況

Recent updates

We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

Dec 31

CEO（最高経営責任者

Matt Kane (47 yo)

less than a year

在職期間

Mr. Matthew R. Kane, also known as Matt, is Chief Executive Officer of Celyad Oncology SA from October 1, 2024. Mr. Kane is the Chief Executive Officer and Director of Tune Therapeutics. Mr. Kane co-founde...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Michel E. Lussier	Co-Founder & Executive Director	no data	€96.31k	0.38% € 156.6k
Matthew Kane	Chief Executive Officer	less than a year	データなし	データなし
David Georges	Vice President of Finance & Administration	2.3yrs	データなし	データなし
Sara Zelkovic	Communications & Investor Relations Director	no data	データなし	データなし
An Phan	Head of Legal	2.3yrs	データなし	データなし
Hannes Iserentant	Head of Intellectual Property	2.3yrs	データなし	データなし
Eytan Breman	Head of R&D	2.4yrs	データなし	データなし
Philippe Dechamps	Corporate Secretary	no data	データなし	データなし

2.3yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: CYADの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Michel E. Lussier	Co-Founder & Executive Director	17.8yrs	€96.31k	0.38% € 156.6k
Hilde Windels	Independent Chairwoman of the Board	7.8yrs	€101.10k	データなし
Serge Goblet	Non-Executive Director	16.8yrs	€15.50k	0.14% € 56.2k
Margo Roberts	Member of Scientific Advisory Board	no data	€10.00k	データなし
Hinrich Abken	Member of Scientific Advisory Board	8.6yrs	データなし	データなし
Marco Davila	Member of Scientific Advisory Board	8.6yrs	データなし	データなし
Marina Blagovic	Independent Director	4.5yrs	€49.50k	データなし
Dominic Piscitelli	Independent Director	4.5yrs	€69.50k	データなし
Ami Shah	Non-Executive Director	2.9yrs	データなし	データなし
Ann Ager	Member of Scientific Advisory Board	no data	データなし	データなし
Christopher LiPuma	Non-Executive Director	2.8yrs	データなし	データなし
Jean-Christophe Marine	Member of Scientific Advisory Board	no data	データなし	データなし

7.8yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: CYADの取締役会は経験豊富であると考えられます ( 7.8年の平均在任期間)。

Celyad Oncology マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Celyad Oncology Appoints Matt Kane as Chief Executive Officer, Effective October 1, 2024

Celyad Oncology Sa Announces Executive Change

Celyad Oncology SA, Annual General Meeting, May 06, 2024

Less than half of directors are independent

Celyad Oncology SA Announces Chief Financial Officer Changes

Celyad Oncology SA Announces Board Changes

Recent updates

Celyad Oncology Appoints Matt Kane as Chief Executive Officer, Effective October 1, 2024

Celyad Oncology SA to Report First Half, 2025 Results on Sep 25, 2025

Celyad Oncology SA to Report First Half, 2024 Results on Sep 20, 2024

Celyad Oncology SA to Report First Half, 2024 Results on Aug 06, 2024

Celyad Oncology Sa Announces Executive Change

Celyad Oncology SA announced that it has received €9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.

Celyad Oncology SA ADR - Sponsored to Be Deleted from OTC Equity

Celyad Oncology SA, Annual General Meeting, May 06, 2024

Celyad Oncology SA to Report First Half, 2023 Results on Sep 04, 2023

Celyad Oncology SA announced that it expects to receive €9.794 million in funding from Fortress Investment Group LLC, Tolefi S.A., and other investors

Nasdaq to Delist the American Depositary Shares of Celyad Oncology

Celyad Oncology Receives Notification Letter from Nasdaq Regarding ADS's Scheduled for Delisting from The Nasdaq Global Market and to be Suspended at the Opening of U.S. Business on May 19, 2023

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares from Nasdaq

Celyad Oncology Announces Publication of Data from Its Phase 1 Think Study of CYAD-01

Celyad Oncology SA to Report Q1, 2023 Results on May 05, 2023

Celyad Oncology SA to Report Q3, 2023 Results on Nov 09, 2023

Less than half of directors are independent

Celyad Oncology Provides Update on Clinical Trial Programs

Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) for €6 million.

Celyad Oncology Sa Announces Fda Lifts Clinical Hold of Cyad-101-002 Phase 1B Trial

Celyad Oncology SA Announces Chief Financial Officer Changes

Celyad Oncology SA Announces Board Changes

Less than half of directors are independent

Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

Celyad Oncology SA Announces Voluntary Pause of CYAD-101-002 Phase 1B Trial

Celyad Oncology SA Announces Program Update and Anticipated Milestones for 2022

Celyad Oncology SA Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial

Consensus forecasts updated

Celyad Oncology SA Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition

Celyad Oncology SA announced that it expects to receive €28.73 million in funding from Fortress Investment Group LLC

Forecast to breakeven in 2023

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Price target decreased to €14.75

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma At the European Hematology Association Virtual Congress

Full year 2020 earnings released: €1.23 loss per share (vs €2.29 loss in FY 2019)

Celyad Oncology SA to Report Fiscal Year 2020 Results on Mar 24, 2021

New 90-day low: €6.42

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

Celyad Oncology SA Appoints Marina Udier, Ph.D., to Board of Directors

Celyad Oncology SA announced that it expects to receive $40 million in funding from Lincoln Park Capital, LLC

We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

Analysts update estimates

Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC

Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma

New 90-day low: €7.64

Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

New 90-day low: €8.13

New 90-day low - €8.34

Earnings released

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24